TITLE

Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans

AUTHOR(S)
Foxx-Orenstein A; Camilleri M; Stephens D; Burton D
PUB. DATE
November 2003
SOURCE
Gut;Nov2003, Vol. 52 Issue 11, p1555
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Pharmacological approaches to alter satiation may have an impact on functional upper gastrointestinal disorders and potentially change food intake in obesity. Aim: Our aim was to compare the effects of two doses of octreotide and placebo on postprandial symptoms, gastric accommodation, and gastric emptying using validated non-invasive techniques. METHODS: In a randomised, parallel group, two dose, double blind, placebo controlled study, 39 healthy participants (13 per group) were randomised to 30 or 100 micro g octreotide or placebo, administered subcutaneously, 30 minutes before each study. Studies were performed on three separate days and included scintigraphic gastric emptying of solids and liquids, (99m)Tc SPECT imaging to measure fasting stomach volume and gastric accommodation following a 300 ml Ensure meal, and a standardised nutrient drink test to measure maximum tolerated volume and postprandial symptoms. RESULTS: Relative to placebo, both doses of octreotide delayed gastric emptying of solids (not liquids), increased fasting gastric volume, reduced the change in gastric volume post meal, and decreased the sensation of fullness after a satiating meal. CONCLUSION: The somatostatin analogue octreotide significantly alters human gastric functions, including inhibition of the normal reflex responses of gastric volume increase and emptying of the meal. These pharmacological effects suggest studies of the medication in disorders of satiation, including obesity and dyspepsia, are warranted.
ACCESSION #
11352942

 

Related Articles

  • Antidepressants Influence Somatostatin Levels and Receptor Pharmacology in Brain. Pallis, Eleftherios; Vasilaki, Anna; Fehlmann, Dominique; Kastellakis, Andreas; Hoyer, Daniel; Spyraki, Christina; Thermos, Kyriaki // Neuropsychopharmacology;Mar2009, Vol. 34 Issue 4, p952 

    This study investigated how the administration (acute and chronic) of the antidepressants citalopram and desmethylimipramine (DMI) influences somatostatin (somatotropin release inhibitory factor, SRIF) levels and SRIF receptor density (sst1–5) in rat brain. Animals received either of the...

  • Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Hogan, Marie C.; Masyuk, Tetyana V.; Page, Linda; Holmes, David R.; Li, Xujian; Bergstralh, Eric J.; Irazabal, Maria V.; Kim, Bohyun; King, Bernard F.; Glockner, James F.; LaRusso, Nicholas F.; Torres, Vicente E. // Nephrology Dialysis Transplantation;Sep2012, Vol. 27 Issue 9, p3532 

    Background We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR®) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver...

  • Effects of Octreotide on Central Hemodynamics and Systemic Oxygen Use in Patients With Viral Cirrhosis. Han-Chieh Lin; Ming-Chih Hou; Wui-Chiang Lee; Yi-Tsau Huang; Fa-Yauh Lee; Full-Young Chang; Yang-Te Tsai; Shou-Dong Lee // American Journal of Gastroenterology;Apr1999, Vol. 94 Issue 4, p1012 

    OBJECTIVE: Octreotide has potentially beneficial effects in patients with cirrhosis. However, the effects of octreotide on central hemodynamics and oxygen use have not been established. The present study was undertaken to evaluate the effect of octreotide on central hemodynamics and oxygen use...

  • 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Capello, Astrid; Krenning, Eric; Bernard, Bert; Reubi, Jean-Claude; Breeman, Wout; de Jong, Marion // European Journal of Nuclear Medicine & Molecular Imaging;Nov2005, Vol. 32 Issue 11, p1288 

    Purpose: Peptide receptor scintigraphy with the radioactive somatostatin analogue 111In-DTPA-octreotide is a sensitive and specific technique to show in vivo the presence of somatostatin receptors on various tumours. Since 111In emits not only gamma rays but also therapeutic Auger and internal...

  • Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. Jia, Wei-Dong; Xu, Ge-Liang; Xu, Rong-Nan; Sun, Hui-Chuan; Wang, Lu; Yu, Ji-Hai; Wang, Jian; Li, Jian-Sheng; Zhai, Zhi-Ming; Xue, Qiong // Journal of Cancer Research & Clinical Oncology;Jun2003, Vol. 129 Issue 6, p327 

    Purpose. To investigate the effect of octreotide on angiogenesis induced by human hepatocellular carcinoma (HCC) and to evaluate whether octreotide can suppress tumor growth in nude mice bearing human HCC xenografts through inhibition of angiogenesis. Methods. Using MTT assay, invasion assay,...

  • Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Reubi, Jean Claude; Sch�r, Jean-Claude; Waser, Beatrice; Wenger, Sandra; Heppeler, Axel; Schmitt, J�rg S.; M�cke, Helmut R. // European Journal of Nuclear Medicine;2000, Vol. 27 Issue 3, p273 

    Abstract. In vive somatostatin receptor scintigraphy using Octreoscan is a valuable method for the visualisation of human endocrine tumours and their metastases. Recently, several new, alternative somatostatin radioligands have been synthesised for diagnostic and radiotherapeutic use in vive....

  • Cardiovascular Effects of the Somatostatin Analog Octreotide in Acromegaly. Chanson, Philippe; Timsit, Jose; Masquet, Christiane; Warnet, Andre; Guillausseau, Pierre-Jean; Birman, Pascal; Harris, Alan G.; Lubetzki, Jean // Annals of Internal Medicine;12/15/90, Vol. 113 Issue 12, p921 

    Determines the cardiovascular effects of the somatostatin analog octreotide in patients with acromegaly. Nature of acromegaly; Discussion on hormonal and hemodynamic values before octreotide treatment; Effects of long-term octreotide therapy.

  • Octreotide Treatment of Acromegaly. Ezzat, Shereen; Snyder, Peter J.; Young, William F.; Boyajy, Louis D.; Newman, Connie; Klibanski, Anne; Molitch, Mark E.; Boyd, Aubrey E.; Sheeler, Leslie; Cook, David M.; Malarkey, William B.; Jackson, Ivor; Vance, Mary Lee; Thorner, Michael O.; Barkan, Ariel; Frohman, Lawrence A.; Melmed, Shlomo // Annals of Internal Medicine;11/1/92, Vol. 117 Issue 9, p711 

    Presents a study which determined the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly. Background on agromegaly; Methodology; Results of the study.

  • COMPARISON OF TERLIPRESSIN AND OCTREOTIDE IN INITIAL MANAGEMENT OF ACUTE VARICEAL BLEEDING. ANSARI, IMDAD ALI; AZIZULLAH JALBANI; SHAH, AFTAB HUSSAIN; GURBAKHSHANI, KOURO MAL; SOLANGI, GHULAM AKBAR; HAIKH, ABRAR // Medical Channel;Jul2010, Vol. 16 Issue 3, p385 

    Most patients due to cirrhosis develop esophageal varices due to portal hypertension and present with acute and often fatal gastrointestinal (G.I) bleeding. The purpose of this study was to establish Octreotide or Terlipressin, as the first line of pharmacological therapies in controlling acute...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics